Biological Significance of Oxidized Neprilysin
氧化脑啡肽酶的生物学意义
基本信息
- 批准号:7140739
- 负责人:
- 金额:$ 6.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-01 至 2008-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The long-term objective of this study is to understand the biological significance of oxidative modification of neprilysin on amyloid deposition in aging and Alzheimer's disease (AD). Amyloid deposition in the brain parenchyma and in vessels is a common phenomenon with advanced age and one of the diagnostic hallmarks for AD. Two possible explanations for excessive beta-amyloid (AB) deposition in aging and AD brains are overproduction and decreased degradation. Although the mechanisms involved in AB production have been extensively studied and the excessive production of AB has been confirmed to play a critical role in the pathogenesis of familial AD cases, there is little evidence so far to suggest that increased brain AB production is important in aging and sporadic AD. Recently, the role of AB degradation has been increasingly studied and several enzymes have been described with a range of abilities to degrade AB. Among them, neprilysin (NEP) has been considered by some a pivotal enzyme for AB degradation. Previous studies have shown that decreased NEP may contribute to the accumulation of AB in AD. Recent data from our group indicated that brain NEP is subject to oxidative modification in both AD and aging. To understand the biological significance of oxidized-NEP it is very important to know if oxidization decreases NEP enzymatic activity. It is also important to know the HNE modification site(s) of NEP to design therapeutic reagents that can block oxidative modification of NEP. Our working hypothesis is that initial amyloid accumulation will lead to HNE production with progressive inhibitory NEP, starting a feed-forward cycle of increasing amyloid accumulation, oxidative stress, and NEP inhibition. To test this hypothesis, as initial steps we propose three specific aims in this RO3 proposal: 1. To determine if human NEP expressed in cultured cells can be modified by exogenous HNE or endogenous HNE induced by synthetic AB; 2. To discover if HNE-modified NEP expressed in cultured cells has decreased enzymatic activity. 3. To identify critical HNE-modification sites which alter NEP activity. Our goal through this RO3 mechanism is to develop enough preliminary data for a future RO1 application that will further explore this hypothesis in animal models and in humans.
描述(由申请人提供):本研究的长期目标是了解脑啡肽酶氧化修饰对衰老和阿尔茨海默病(AD)中淀粉样蛋白沉积的生物学意义。脑实质和血管中的淀粉样蛋白沉积是老年人的常见现象,也是AD的诊断标志之一。在衰老和AD大脑中过量β-淀粉样蛋白(AB)沉积的两种可能的解释是过度生产和降解减少。虽然参与AB生产的机制已被广泛研究,并已证实AB的过度生产在家族性AD病例的发病机制中起着关键作用,但到目前为止,很少有证据表明,大脑AB生产增加在衰老和散发性AD中是重要的。最近,人们越来越多地研究AB降解的作用,并且已经描述了几种具有一系列降解AB能力的酶。其中,脑啡肽酶(NEP)被认为是AB降解的关键酶。以往的研究表明,NEP降低可能有助于AD中AB的积累。我们小组最近的数据表明,大脑NEP在AD和衰老中都受到氧化修饰。为了理解氧化的NEP的生物学意义,了解氧化是否降低NEP酶活性是非常重要的。了解NEP的HNE修饰位点以设计可以阻断NEP的氧化修饰的治疗试剂也是重要的。我们的工作假设是,最初的淀粉样蛋白积累将导致HNE的生产与渐进的抑制性NEP,开始一个前馈循环增加淀粉样蛋白积累,氧化应激,和NEP抑制。为了验证这一假设,作为初始步骤,我们在RO 3提案中提出了三个具体目标:1。目的:1.确定外源性HNE或人工合成AB诱导的内源性HNE能否修饰培养细胞中表达的人NEP。发现在培养细胞中表达的HNE修饰的NEP是否具有降低的酶活性。3.确定改变NEP活性的关键HNE修饰位点。我们的目标是通过这种RO 3机制为未来的RO 1应用开发足够的初步数据,以进一步探索动物模型和人类的这一假设。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DENGSHUN WANG其他文献
DENGSHUN WANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DENGSHUN WANG', 18)}}的其他基金
Biological and clinical significance of tTG and isopeptide in AD
tTG 和异肽在 AD 中的生物学和临床意义
- 批准号:
7530370 - 财政年份:2008
- 资助金额:
$ 6.47万 - 项目类别:
Biological and clinical significance of tTG and isopeptide in AD
tTG 和异肽在 AD 中的生物学和临床意义
- 批准号:
7661626 - 财政年份:2008
- 资助金额:
$ 6.47万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 6.47万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 6.47万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 6.47万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 6.47万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 6.47万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 6.47万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 6.47万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 6.47万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 6.47万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 6.47万 - 项目类别: